Online inquiry

IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5216MR)

This product GTTS-WQ5216MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Hairy cell leukemia (HCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5216MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ479MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ8971MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ3072MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ15630MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ13071MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8975MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ15959MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ1729MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW